EGFR and neoplasm: Similar to AMT-562, DB-1310 was also shown to synergize with osimertinib in EGFR-mutant NSCLC cell line xenografts and dramatically suppressed tumor growth in an osimertinib-resistant NSCLC PDX model [133].